# A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

> **NCT05364944** · PHASE1 · TERMINATED · sponsor: **Debiopharm International SA** · enrollment: 19 (actual)

## Conditions studied

- Acromegaly
- GEP-NET

## Interventions

- **DRUG:** Debio 4126
- **DRUG:** Sandostatin LAR
- **DRUG:** Somatuline ATG

## Key facts

- **NCT ID:** NCT05364944
- **Lead sponsor:** Debiopharm International SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-05-18
- **Primary completion:** 2024-10-29
- **Final completion:** 2024-12-03
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** The recruitment was halted for strategic reasons
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05364944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05364944, "A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05364944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*